---

• Pine Brook, NJ


• Contact:
  Ron Eastman
  
• Formerly Known As: E-Site Therapeutics
• Acquisition
• Acquired by: NightHawk Biosciences
• 

Related News

• Elusys Therapeutics’ Anthrax Drug Gains FDA Approval in Adults and Children
• Elusys Therapeutics Receives First Delivery Order from US Government for Anthim
• Elusys Awarded Additional $16 Million To Complete Development of Lyophilized Form of Anthim
• Elusys Therapeutics Presents Efficacy Results and Other Key Findings on ETI-204 Anthrax Anti-Toxin
• Elusys Awarded Additional $14.5Million Under Existing US Government Contracts
• Elusys Awarded Additional $50.2 Million Under Existing U.S. Government Contract To Support ETI-204
• Elusys Awarded $68 Million Contract To Develop Anthim For Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection